Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 5/20 | 0.82 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.70 |
| ▸ | BCHE | P06276 | 2/20 | 0.68 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.67 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2992884 | 1.00 | P4HB (0.82) | P4HBNR1H4USP2CYP1A1CYP1A2 | |
| 3-Hydroxy Chalcone SCHEMBL1524800 | 0.91 | P4HB (0.74) | P4HBCYP1A1CYP1A2CYP1B1BCHE | |
| SCHEMBL5593205 | 0.91 | P4HB (0.79) | P4HBNR1H4USP2CYP1B1BCHE | |
| 3-Hydroxy Chalcone SCHEMBL1524799 | 0.91 | P4HB (0.74) | P4HBCYP1A1CYP1A2CYP1B1BCHE | |
| SCHEMBL6639007 | 0.91 | P4HB (0.79) | P4HBNR1H4USP2CYP1B1BCHE | |
| 3-Hydroxy Chalcone SCHEMBL25235759 | 0.91 | P4HB (0.74) | P4HBCYP1A1CYP1A2CYP1B1BCHE | |
| SCHEMBL9390190 | 0.89 | P4HB (0.71) | P4HBNR1H4USP2CYP1A1CYP1A2 | |
| SCHEMBL14290490 | 0.89 | MAOB (0.75) | P4HBNR1H4USP2CYP1A1CYP1A2 | |
| SCHEMBL8223107 | 0.89 | P4HB (0.71) | P4HBNR1H4USP2CYP1A1CYP1A2 | |
| SCHEMBL8223103 | 0.89 | P4HB (0.71) | P4HBNR1H4USP2CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6122623-A | — | — | None | — | — | JP | disclosed |
| US-12569530-B2 | Tannin-based antiproliferative pharmaceutical | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2026-03-10 | — | — | US | disclosed |
| US-12453799-B1 | Bioadhesive for medical and dental applications | IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) | 2025-10-28 | — | — | US | disclosed |
| US-20250249063-A1 | METHOD FOR TREATING ORAL CANCER | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2025-08-07 | — | — | US | disclosed |
| US-12318422-B2 | Tannin-based antiproliferative pharmaceutical | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2025-06-03 | — | — | US | disclosed |
| US-20240293492-A1 | TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2024-09-05 | — | — | US | disclosed |
| US-20230210931-A1 | TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-07-06 | — | — | US | disclosed |
| US-11376570-B1 | Method of forming copper oxide-on-copper nanomaterial catalyst mesh | KING ABDULAZIZ UNIVERSITY (SA) | 2022-07-05 | — | — | US | disclosed |
| US-11311492-B1 | Carbon nanomedicine with natural ligands | KING ABDULAZIZ UNIVERSITY (SA) | 2022-04-26 | — | — | US | disclosed |
| US-11234940-B1 | Method for making a noble metal nanomedicine | KING ABDULAZIZ UNIVERSITY (SA) | 2022-02-01 | — | — | US | disclosed |
| US-11219605-B1 | Metal nanoparticle medicine with a mixture of natural ligands | KING ABDULAZIZ UNIVERSITY (SA) | 2022-01-11 | — | — | US | disclosed |
| US-11129797-B1 | Catechin and gingerol loaded nanomedicine | KING ABDULAZIZ UNIVERSITY (SA) | 2021-09-28 | — | — | US | disclosed |
| WO-2014007447-A1 | COMPOSITION FOR PREVENTING OR TREATING DISEASES CAUSED BY ANGIOGENESIS, CONTAINING HYDROXYCHALCONE COMPOUND AS ACTIVE INGREDIENT | 영남대학교 산학협력단 (KR) | 2014-01-09 | — | — | WO | disclosed |
| US-7787085-B2 | Optical alignment method and liquid crystal display element | JSR CORPORATION (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20080123046-A1 | OPTICAL ALIGNMENT METHOD AND LIQUID CRYSTAL DISPLAY ELEMENT | JSR CORPORATION (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20050259203-A1 | Optical alignment method and liquid crystal display element | JSR CORPORATION (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1353217-A1 | Optical alignment method and liquid crystal display element | JSR Corporation (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-6224788-B1 | AROMATIC UNSATURATED KETONE POLYMERS | JSR CORPORATION (JP) | 2001-05-01 | — | — | US | disclosed |
| JP-H06122623-A | ANTINEOPLASTIC AGENT | MINOFUAAGEN SEIYAKU HONPO:GOUSHI | 1994-05-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250249063-A1 | METHOD FOR TREATING ORAL CANCER | UGGT1, G6PD, UGT1A3 | P4HB 4127/4885NR1H4 3646/4885USP2 3165/4885 |
| US-20240293492-A1 | TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL | UGGT1, G6PD, UGDH | P4HB 4634/4885NR1H4 4356/4885USP2 3399/4885 |
| US-12569530-B2 | Tannin-based antiproliferative pharmaceutical | SLC2A3, SLC2A1, SLC2A8 | P4HB 3488/4885NR1H4 3889/4885USP2 3189/4885 |
| US-20230210931-A1 | TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL | UGGT1, G6PD, UGDH | P4HB 4634/4885NR1H4 4356/4885USP2 3399/4885 |
| US-12318422-B2 | Tannin-based antiproliferative pharmaceutical | UGGT1, G6PD, UGDH | P4HB 4634/4885NR1H4 4356/4885USP2 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.